ClinicalTrials.gg
WithdrawnNCT01061372Updated Jan 22, 2021

12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects

A Phase 3 interventional study of Placebo and pregabalin in Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.

02

Conditions studied

  • Restless Legs Syndrome

Keywords

  • RLS
03

In context

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic Restless Legs Syndrome with the presence of all four clinical manifestations of RLS:
  • RLS symptoms occur predominantly in the evening
  • RLS history at least 6 months
  • International Restless Legs Study Group Rating Scale (IRLS) greater than or equal to 15 at the beginning and the end of placebo run-in
  • Have greater than or equal to 15 nights with RLS symptoms in the month prior to screening

Exclusion criteria

Exclusion Criteria:

  • Any secondary RLS
  • Current augmentation due to RLS treatment
  • Placebo responders identified during the placebo run-in
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Pregabalin 150 mg/day

    Drug: pregabalin

  • Experimental
    Pregabalin 300 mg/day

    Drug: pregabalin

Interventions

  • DrugPlacebo

    Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks

  • pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks

    Also known as: Lyrica

  • pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks

    Also known as: Lyrica

06

What researchers measure

Primary outcomes

  1. Changes from baseline in RLS symptom severity using the International Restless Leg Group Rating Scale (IRLS) total score for efficacy assessment

    Time frame: up to 12 weeks

  2. The proportion of subjects responding to treatment using the Clinical Global Impression - Improvement (CGI-I) scale for efficacy assessment

    Time frame: up to 12 weeks

Secondary outcomes

  1. Subjective Sleep Questionnaire (SSQ - Subjective WASO)

    Time frame: up to 12 weeks

  2. RLS Next Day Impact (RLS-NDI)

    Time frame: up to 12 weeks

  3. Limb pain rating using a numerical rating scale (Limb Pain - NRS)

    Time frame: up to 12 weeks

  4. Clinical Global Impressions - Severity (CGI-S)

    Time frame: up to 12 weeks

  5. Medical Outcomes Study - Sleep Scale (MOS - SS)

    Time frame: up to 12 weeks

  6. Impact on Life (IRLS symptom impact sub-score)

    Time frame: up to 12 weeks

  7. RLS-Quality of Life Scale (RLS-QoL)

    Time frame: up to 12 weeks

  8. Medical Outcomes Study - Short Form 36 (SF-36)

    Time frame: up to 12 weeks

  9. Work Productivity and Activity Impairment - Specific Health Problem (WPAI-SHP)

    Time frame: up to 12 weeks

  10. Profile of Mood States (POMS)

    Time frame: up to 12 weeks

  11. Adverse events from spontaneous reports will be monitored throughout the trial and summarized by treatment group

    Time frame: up to 12 weeks

  12. Sheehan Suicidality Tracking Scale (S-STS) will be utilized to assess the risk of suicide

    Time frame: up to 12 weeks

  13. Changes in RLS symptoms following the discontinuation of study drug at the end of treatment will be evaluated by collection of the IRLS scores at the end of the drug taper period at Week 13

    Time frame: week 13

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2010
First posted
Feb 3, 2010
Start
May 2010
Primary completionEst.
Aug 2011
CompletionEst.
Aug 2011
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01061372
Responsible party
Sponsor
First posted
Feb 3, 2010
Start date
May 2010
Primary completion
Aug 2011 (estimated)
Completion
Aug 2011 (estimated)
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion